Loading clinical trials...
Loading clinical trials...
The purpose of this study is to assess the safety and tolerability of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4) XL647 when given orally daily to ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Kadmon Corporation, LLC
NCT07671846 · Cancer
NCT06689488 · Lung Cancer
NCT07209917 · Cervical Cancer, Human Papillomavirus (HPV) Infection, and more
NCT06079671 · Locally Advanced Cervical Cancer
NCT06274047 · Androgen Axis Suppression, Prostatectomy, and more
Stanford University Medical Center
Stanford, California
Mayo Clinic
Rochester, Minnesota
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions